South Africa urged by advocates to issue compulsory license for Gilead HIV prevention drug

Taking stock of the drug industry, from the lab to the medicine chest

November 20, 2025 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Nardus Engelbrecht/AP STAT+ | South Africa is urged by advocates to issue a compulsory license for Gilead's HIV prevention drug Patient advocates argue South Africa would be able to control its own destiny if the government licenses domestic production. By Ed Silverman STAT+ | Abbott to buy cancer screening test maker Exact Sciences in $21B deal The deal, one of the biggest health care acquisitions this year, includes Exact's blood-based and stool-based cancer tests. By Andrew Joseph STAT+ | In new FDA role, Pazdur will decide the future of Sarepta's Duchenne drugs In this week's edition of "Adam's Biotech Scorecard," Adam also lays out what he's grateful for in biotech this Thanksgiving season. By Adam Feuerstein Adobe STAT+ | AI spun out of Berkeley proposes to detect hundreds of conditions on medical images Radiologist and computer scientist team up in attempt to turn an open-source AI model into software that can spot hundreds of conditions on CT, MRI scans. By Casey Ross

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2025, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser